Effects of multifunctional antioxidants on mitochondrial dysfunction and amyloid-β metal dyshomeostasis

Journal of Alzheimer's Disease

Volumn 44, Issue 1, 2015, Pages 297-307

  Kawada, Hiroyoshi ^a   Blessing, Karen ^a   Kiyota, Tomomi ^b   Woolman, Theodor ^a   Winchester, Lee ^a   Kador, Peter F ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Age related macular degeneration; Alzheimer's disease; Amyloid ; Clioquinol; JAX transgenic Alzheimer mouse; Mitochondrial dysfunction; Multifunctional antioxidants

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ANTIOXIDANT; GELATINASE A; MANGANESE; MANGANESE CHLORIDE; METAL; RHODAMINE 123; ZINC; ZINC COMPLEX; FLUORESCENT DYE; MMP2 PROTEIN, HUMAN; QUINOLONE DERIVATIVE; TOLUENESULFONIC ACID DERIVATIVE; ZINQUIN;

AGE RELATED MACULAR DEGENERATION; ALZHEIMER DISEASE; AMYLOID BETA METAL DYSHOMEOSTASIS; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; BRAIN LEVEL; COMPLEX FORMATION; CONTROLLED STUDY; CYTOPLASM; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; STAINING; TRANSGENIC MOUSE; ANIMAL; DIAGNOSTIC USE; DISEASE MODEL; DRUG EFFECTS; EPITHELIUM CELL; METABOLISM; MITOCHONDRION; NEUROBLASTOMA; PATHOLOGY; TUMOR CELL LINE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIOXIDANTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; FLUORESCENT DYES; HUMANS; MATRIX METALLOPROTEINASE 2; MICE; MICE, TRANSGENIC; MITOCHONDRIA; NEUROBLASTOMA; QUINOLONES; RHODAMINE 123; TOSYL COMPOUNDS; ZINC;

EID: 84920771154     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132471     Document Type: Article

References (50)

1. Alzheimer's Association (2012) 2012 Alzheimer's disease facts and figures. Alzheimers Dement 8, 131-168.
2. Hardy J (2009) The amyloid hypothesis for Alzheimer's disease: A critical reappraisal. J Neurochem 110, 1129-1134.
3. Hardy JA, Higgins GA (1992) Alzheimer's disease: The amyloid cascade hypothesis. Science 256, 184-185.
4. Citron M (2010) Alzheimer's disease: Strategies for disease modification. Nat Rev Drug Discov 9, 387-398.
5. Castellani RJ, Perry G (2012) Pathogenesis and diseasemodifying therapy in Alzheimer's disease: The flat line of progress. Arch Med Res 43, 694-698.
6. Bush AI (2003) The metallobiology of Alzheimer's disease. Trends Neurosci 26, 207-214.
7. Bush AI, Pettingell WH, Multhaup G, d Paradis M, Vonsattel JP, Gusella JF, Beyreuther K, Masters CL, Tanzi RE (1994) Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 265, 1464-1467.
8. Crouch PJ, Savva MS, Hung LW, Donnelly PS, Mot AI, Parker SJ, Greenough MA, Volitakis I, Adlard PA, Cherny RA, Masters CL, Bush AI, Barnham KJ, White AR (2011) The Alzheimer's therapeutic PBT2 promotes amyloid-beta degradation and GSK3phosphorylation via a metal chaperone activity. J Neurochem 119, 220-230.
9. Cuajungco MP, Goldstein LE, Nunomura A, Smith MA, Lim JT, Atwood CS, Huang X, Farrag YW, Perry G, Bush AI (2000) Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. J Biol Chem 275, 19439-19442.
10. Smith DG, Cappai R, Barnham KJ (2007) The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim Biophys Acta 1768, 1976-1990.
11. Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, Laughton K, Li QX, Charman SA, Nicolazzo JA, Wilkins S, Deleva K, Lynch T, Kok G, Ritchie CW, Tanzi RE, Cappai R, Masters CL, Barnham KJ, Bush AI (2008) Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59, 43-55.
12. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30, 665-676.
13. RitchieCW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial. Arch Neurol 60, 1685-1691.
14. Regland B, Lehmann W, Abedini I, Blennow K, Jonsson M, Karlsson I, Sjogren M, Wallin A, Xilinas M, Gottfries CG (2001) Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord 12, 408-414.
15. RitchieCW, Bush AI, Masters CL (2004) Metal-protein attenuating compounds and Alzheimer's disease. Expert Opin Investig Drugs 13, 1585-1592.
16. Crouch PJ, Barnham KJ (2012) Therapeutic redistribution of metal ions to treat Alzheimer's disease. Acc Chem Res 45, 1604-1611.
17. Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo. J, Harrison J, Lannfelt L, Blennow K, Zetterberg H, Ingelsson M, Masters CL, Tanzi RE, Cummings JL, Herd CM, Bush AI (2010) PBT2 rapidly improves cognition in Alzheimer's disease: Additional phase II analyses. J Alzheimers Dis 20, 509-516.
18. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW, group PEs (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: A phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7, 779-786.
19. Sampson EL, Jenagaratnam L, McShane R (2012) Metal protein attenuating compounds for the treatment of Alzheimer's dementia. Cochrane Database Syst Rev 5, CD005380.
20. Rodriguez-Rodriguez C, Telpoukhovskaia M, Orvig C (2012) The art of building multifunctional metal-binding agents from basic molecular scaffolds for the potential application in neurodegenerative diseases. Coord Chem Rev 256, 2308-2332.
21. Kador PF (2013) Protective multifunctional antioxidants, Application number 28430-10. US Patent and Trademark Office, USA.
22. Jin H, Randazzo J, Zhang P, Kador PF (2010) Multifunctional antioxidants for the treatment of age-related diseases. J Med Chem 53, 1117-1127.
23. Randazzo. J, Zhang P, Makita J, Blessing K, Kador PF (2011) Orally active multi-functional antioxidants delay cataract formation in streptozotocin (type 1) diabetic and gammairradiated rats. PloS One 6, e18980.
24. Randazzo J, Zhang Z, Hoff M, Kawada H, Sachs A, Yuan Y, Haider N, Kador P (2011) Orally active multi-functional antioxidants are neuroprotective in a rat model of lightinduced retinal damage. PloS One 6, e21926.
25. Kawada H (2013) Multi-functional antioxidants targeting neurodegenerative diseases (doctoral thesis). Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA.
26. JohnsonLV, WalshML, ChenLB(1980) Localization of mitochondria in living cells with rhodamine 123. Proc Natl Acad Sci U S A 77, 990-994.
27. Bantseev V, McCanna DJ, Driot JY, Ward KW, Sivak JG (2007) Biocompatibility of contact lens solutions using confocal laser scanning microscopy and the in vitro bovine cornea. Eye Contact Lens 33, 308-316.
28. Bantseev V, Youn HY (2006) Mitochondrial "movement" and lens optics following oxidative stress from UV-B irradiation: Cultured bovine lenses and human retinal pigment epithelial cells (ARPE-19) as examples. Ann N Y Acad Sci 1091, 17-33.
29. Crouch PJ, Tew DJ, Du T, Nguyen DN, Caragounis A, Filiz G, Blake RE, Trounce IA, Soon CP, Laughton K, Perez KA, Li QX, Cherny RA, Masters CL, Barnham KJ, White AR (2009) Restored degradation of the Alzheimer's amyloid-beta peptide by targeting amyloid formation. J Neurochem 108, 1198-1207.
30. Ciccotosto GD, Tew D, Curtain CC, Smith D, Carrington D, Masters CL, Bush AI, Cherny RA, Cappai R, Barnham KJ (2004) Enhanced toxicity and cellular binding of a modified amyloid beta peptide with a methionine to valine substitution. J Biol Chem 279, 42528-42534.
31. Haase H, Beyersmann D (1999) Uptake and intracellular distribution of labile and total Zn(II) in C6 rat glioma cells investigated with fluorescent probes and atomic absorption. Biometals 12, 247-254.
32. Lee JY, Cole TB, Palmiter RD, Suh SW, Koh JY (2002) Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc Natl Acad Sci U S A 99, 7705-7710.
33. Suh SW, Jensen KB, Jensen MS, Silva DS, Kesslak PJ, Danscher G, Frederickson CJ (2000) Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Brain Res 852, 274-278.
34. StoltenbergM, Bush AI, Bach G, Smidt K, Larsen A, Rungby. J, Lund S, Doering P, Danscher G (2007) Amyloid plaques arise from zinc-enriched cortical layers in APP/PS1 transgenic mice and are paradoxically enlarged with dietary zinc deficiency. Neuroscience 150, 357-369.
35. Greenough MA, Camakaris J, Bush AI (2013) Metal dyshomeostasis and oxidative stress in Alzheimer's disease. Neurochem Int 62, 540-555.
36. Dunaief JL, Richa C, Franks EP, Schultze RL, Aleman TS, Schenck JF, Zimmerman EA, Brooks DG (2005) Macular degeneration in a patient with aceruloplasminemia, a disease associated with retinal iron overload. Ophthalmology 112, 1062-1065.
37. Anderson DH, Talaga KC, Rivest AJ, Barron E, Hageman GS, Johnson LV (2004) Characterization of beta amyloid assemblies in drusen: The deposits associated with aging and age-related macular degeneration. Exp Eye Res 78, 243-256.
38. Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH (2002) The Alzheimer's A beta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci U S A 99, 11830-11835.
39. Brown GC (1992) Control of respiration and ATP synthesis in mammalian mitochondria and cells. Biochem J 284(Pt 1), 1-13.
40. Britton RS, Leicester KL, Bacon BR (2002) Iron toxicity and chelation therapy. Int J Hematol 76, 219-228.
41. Yoon YS, Cho H, Lee JH, Yoon G (2004) Mitochondrial dysfunction via disruption of complex II activity during iron chelation-induced senescence-like growth arrest of Chang cells. Ann N Y Acad Sci 1011, 123-132.
42. Foster KA, Galeffi F, Gerich FJ, Turner DA, Muller M (2006) Optical and pharmacological tools to investigate the role of mitochondria during oxidative stress and neurodegeneration. Prog Neurobiol 79, 136-171.
43. Hernandez RB, Farina M, Esposito BP, Souza-Pinto NC, Barbosa F Jr, Sunol C (2011) Mechanisms of manganese-induced neurotoxicity in primary neuronal cultures: The role of manganese speciation and cell type. Toxicol Sci 124, 414-423.
44. Quintanar L (2008) Manganese neurotoxicity:Abioinorganic chemist's perspective. Inorganica Chimica Acta 361, 875-884.
45. Benedetto A, Au C, Aschner M (2009) Manganese-induced dopaminergic neurodegeneration: Insights into mechanisms and genetics shared with Parkinson's disease. Chem Rev 109, 4862-4884.
46. Yin Z, Aschner JL, dos Santos AP, Aschner M (2008) Mitochondrial-dependent manganese neurotoxicity in rat primary astrocyte cultures. Brain Res 1203, 1-11.
47. Howe P, Malcolm H, Dobson S (2004) Manganese and Its Compounds: Environmental Aspects. World Health Organization, Geneva, Switzerland.
48. Coyle P, Zalewski PD, Philcox JC, Forbes IJ, Ward AD, Lincoln SF, Mahadevan I, Rofe AM (1994) Measurement of zinc in hepatocytes by using a fluorescent probe, zinquin: Relationship to metallothionein and intracellular zinc. Biochem J 303(Pt 3), 781-786.
49. Zalewski PD, Forbes IJ, Betts WH (1993) Correlation of apoptosis with change in intracellular labile Zn(II) using zinquin [(2-methyl-8-p-toluenesulphonamido-6- quinolyloxy)acetic acid], a new specific fluorescent probe for Zn(II). Biochem J 296(Pt 2), 403-408.
50. White AR, Du T, Laughton KM, Volitakis I, Sharples RA, Xilinas ME, Hoke DE, Holsinger RM, Evin G, Cherny RA, Hill AF, Barnham KJ, Li QX, Bush AI, Masters CL. (2006) Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J Biol Chem 281, 17670-17680.